Navigation Links
Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biosciences
Date:11/29/2016

ROCKVILLE, Md., Nov. 29, 2016 /PRNewswire/ -- Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development, announced today that the company has entered into a definitive agreement to acquire the assets of Omnia Biologics, Inc. (Omnia), including Omnia's cGMP facility and equipment. The financial terms of the transaction were not disclosed.

The assets acquired by Vigene from Omnia will include a 7,000 square-foot laboratory space, including three cGMP manufacturing suites and one process development laboratory for viral vector production, including AAV, lentivirus and adenovirus. Vigene will also acquire Omnia's cGMP quality system and personnel qualified for manufacturing clinical grade viral vectors.

"We are pleased to have taken this step to expand our cGMP capacity and capability," stated Dr. Zairen Sun, Vigene's CEO. "We believe that the cGMP capability and capacity complement the current strong position of Vigene in the viral vector research reagent market. We plan to take full advantage of our new cGMP facilities by exploring and developing new partnerships with biotech and pharmaceutical companies to further their gene and cell therapy pipeline development."

"Vigene is the perfect company to acquire Omnia," stated Dr. Dale VanderPutten, President and CEO of Omnia. "We feel strongly that this transaction will catapult Vigene into a leading position in cGMP vector production. The fact that Vigene's existing facilities are in close proximity to Omnia's cGMP facility will be conducive to the integration of the Omnia assets and personnel into the Vigene business."

Shulman, Rogers, Gandal, Pordy & Ecker, P.A. served as legal advisor to Vigene in the transaction.

About Vigene Biosciences

Vigene Biosciences, Inc is a leader in viral vector based gene delivery for both life science research, gene therapy and cell therapy purposes. Headquartered in Rockville, Maryland, Vigene offers AAV, lentivirus and adenovirus based products and custom services. Both research grade and cGMP grade AAV, lentiviral and adenoviral vectors are available. Please visit www.vigenebio.com

About Omnia Biologics

Omnia Biologics, Inc offers cGMP production and process development services for gene therapeutics through commercial recombinant proteins. Headquartered in Rockville, Maryland, the company has both non-cGMP and cGMP facilities for process development through Phase I/II manufacture. Please visit www.omniabiologics.com

Contact Information

Jeffrey Hung, Ph.D. 

Chief Commercial Officer

Vigene Biosciences

301-251-6638

jhung@vigenebio.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vigene-biosciences-acquires-the-cgmp-manufacturing-facility-and-assets-of-omnia-biosciences-300368062.html


'/>"/>
SOURCE Vigene Biosciences
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical Officer
2. DuPont Industrial Biosciences and MIAVIT Announce Supply Agreement for Biogas Enzymes
3. Agro BioSciences Expands Probiotic Strain Portfolio
4. ARMO BioSciences Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer
5. DuPont Industrial Biosciences Launches New DuPont™ SYNERXIA® Fermentation System
6. Vortex Biosciences Appoints Dr. Massimo Cristofanilli As Chairman of Newly Formed Scientific Advisory Board
7. Proove Biosciences Appoints John Steiner to Board of Directors
8. The ART BMC System by Celling Biosciences Is Revolutionizing the Practice of Cell Therapy
9. Proove Biosciences Acquires Algynomics, Inc.
10. Proove Biosciences Announces Strategic Partnership with McGill University to Study Link between Pain and Genetics
11. Dr. Nancy Gillett Joins Flagship Biosciences' Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2018)... ... September 10, 2018 , ... Franz Inc. , ... technology, AllegroGraph , for Knowledge Graphs, and Semantic Web Company , developers ... today announced a partnership to develop the Noam Chomsky Knowledge Graph. This ...
(Date:9/7/2018)... ... September 06, 2018 , ... The Discovery on Target (DOT) ... “The industry’s preeminent event on novel drug targets.” BellBrook Labs’ high throughput screening ... these emerging targets in a quest to find new treatments for disease. , ...
(Date:8/31/2018)... ... August 29, 2018 , ... ... the University of Southampton and the Institute of Industrial Science, the University of ... can dramatically accelerate the exploration and study of hard to reach deep sea ...
(Date:8/29/2018)... (PRWEB) , ... August 28, 2018 , ... ... be presenting the results of a safety study performed on an allogeneic (donor ... American Veterinary Regenerative Medicine Association (NAVRMA) conference in September. He is also ...
Breaking Biology Technology:
(Date:9/24/2018)... ... September 24, 2018 , ... Energetiq Technology, a world ... announce that starting on October 1, 2018 Hamamatsu will distribute the company’s Laser-Driven ... have been working steadfastly since our acquisition to integrate with Hamamatsu and familiarize ...
(Date:9/22/2018)... ... 2018 , ... Slone Partners, the leading executive search firm ... completion of the Third Annual Life Serve Youth Foundation (LSYF) Tennis Camp. The ... youth. The 60 participants are primarily inner-city teens living in the New York ...
(Date:9/22/2018)... ... September 20, 2018 , ... Global molecular diagnostics company Omixon, ... collaboration to deliver the first integrated epitope determination and matching service that leverages ... the first time, fully characterized HLA sequences and their corresponding 4-field HLA typings ...
Breaking Biology News(10 mins):